Publicacions en què col·labora amb Juan María González Lahoz (70)

2011

  1. Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance

    Journal of Viral Hepatitis, Vol. 18, Núm. 1, pp. 11-16

  2. Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis

    Journal of Viral Hepatitis, Vol. 18, Núm. 8, pp. 542-548

2010

  1. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes

    Journal of Viral Hepatitis, Vol. 17, Núm. 12, pp. 866-871

  2. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 4, pp. 1647-1649

  3. Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial

    HIV Clinical Trials, Vol. 11, Núm. 4, pp. 197-204

  4. The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring

    Therapeutic Drug Monitoring, Vol. 32, Núm. 2, pp. 242-244

2009

  1. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: Influence of HIV infection

    Journal of Viral Hepatitis, Vol. 16, Núm. 11, pp. 790-795

  2. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients

    HIV Medicine, Vol. 10, Núm. 1, pp. 53-59

2008

  1. Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir

    Clinical Infectious Diseases, Vol. 46, Núm. 11, pp. 1782-1785

  2. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 1, pp. 200-205

  3. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 3, pp. 699-704

  4. Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin

    AIDS, Vol. 22, Núm. 18, pp. 2535-2537

  5. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 4, pp. 816-822

2007

  1. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis

    Journal of Viral Hepatitis, Vol. 14, Núm. 6, pp. 392-395

  2. Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study

    AIDS Research and Human Retroviruses, Vol. 23, Núm. 10, pp. 1237-1241

  3. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

    AIDS, Vol. 21, Núm. 1, pp. 41-46

  4. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C

    Journal of Infectious Diseases, Vol. 195, Núm. 7, pp. 973-979

  5. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy

    AIDS, Vol. 21, Núm. 5, pp. 583-588

  6. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis

    Journal of Infectious Diseases, Vol. 195, Núm. 8, pp. 1181-1183

  7. Update on the treatment of chronic hepatitis C in HIV-infected patients

    AIDS Reviews, Vol. 9, Núm. 2, pp. 99-113